检索结果-南通市图书馆

Progress in studies of huperzine A,a natural cholinesterase inhibitor from chinese herbal medicine

Acta Pharmacologica Sinica 2006年第1期27卷 1-26页

作者： rui wang hart yan xi-can tang state key lahoratory of drug research.shanghai institute of materia medica.shanghai institutes for biological sciences chinese academy of sciences.shanghai 201203,china statekeyLaboratoryofdrugresearch ShanghaiInstituteofMateriaMedicaShanghaiInstitutesforBiologicalSciencesChineseAcademyofSciencesShanghai201203China

Huperzine A (HupA),a novel alkaloid isolated flom the chinese herb Huperziaserrata,is a potent,highly specific and reversible inhibitor of acetylcholinesterase(ACHE).Compared with tacrine,donepezil,and rivastigmine,HupA has betterpenetration through the blood-brain barrier,higher oral bioavailability,and longerduration of AChE inhibitory *** has been found to improve cognitivedeficits in a broad range of animal *** possesses the ability to protectcells against hydrogen peroxide,β-amyloid protein (or peptide),glutamate,ischemia and staurosporine-induced cytotoxicity and *** protec-tive effects are related to its ability to attenuate oxidative stress,regulate theexpression of apoptotic proteins ***,P53,and caspase-3,protectmitochondria,upregulate nerve growth factor and its receptors,and interfere withamyloid precursor protein *** effects of HupA on N-me-thyl-D-aspartate receptors and potassium currents may also contribute to itsneuroprotection as *** studies in rodents,canines,and healthyhuman volunteers indicated that HupA was absorbed rapidly,distributed widelyin the body,and eliminated at a moderate rate with the property of slow andprolonged release after oral *** and clinical safety tests showedthat HupA had no unexpected toxicity,particularly the dose-limiting hepalotoxic-ity induced by *** phase Ⅳ clinical trials in china have demonstratedthat HupA significantly improved memory deficits in elderly people with benignsenescent forgetfulness,and patients with Alzheimer disease and vasculardementia,with minimal peripheral cholinergic side effects and no *** can also be used as a protective agent against organophosphateintoxication.

关键词： huperzine A Alzheimer disease acetylcholinesterase cholinesterase inhibitors cognitive enhancer neuroprotect agents oxidative stress apoptosis

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

The chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

引用

cancer Communications 2024年第1期44卷 127-172页

作者： Feng-Hua wang xiao-Tian Zhang Lei tang Qi Wu Mu-yan Cai Yuan-Fang Li xiu-Juan Qu Hong Qiu Yu-Jing Zhang Jie-Er Ying Jun Zhang Ling-Yu Sun Rong-Bo Lin Chang wang Hao Liu Miao-Zhen Qiu Wen-Long Guan Sheng-xiang Rao Jia-Fu Ji yan xin Wei-Qi Sheng Hui-Mian Xu Zhi-Wei Zhou Ai-Ping Zhou Jing Jin xiang-Lin Yuan Feng Bi Tian-Shu Liu Han Liang yan-Qiao Zhang Guo-xin Li Jun Liang Bao-rui Liu Lin Shen Jin Li rui-Hua Xu Department of medical Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer HospitalBeijingP.R.China Department of Radiology Peking University Cancer HospitalBeijingP.R.China Department of Endoscopy Center Peking University Cancer HospitalBeijingP.R.China Department of Pathology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center of Cancer MedicineGuangzhouGuangdongP.R.China Department of Gastric Surgery Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Department of medical Oncology The First Hospital of China Medical UniversityShenyangLiaoningP.R.China Department of medical Oncology Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhanHubeiP.R.China Department of Radiotherapy Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Department of medical Oncology Zhejiang Cancer HospitalHangzhouZhejiangP.R.China Department of medical Oncology Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiP.R.China Department of Surgical Oncology The Fourth Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiangP.R.China Department of medical Oncology Fujian Cancer HospitalFuzhouFujianP.R.China Tumor Center The First Hospital of Jilin UniversityChangchunJilinP.R.China Department of General Surgery Nanfang HospitalSouthern Medical UniversityGuangzhouGuangdongP.R.China Department of Radiology Zhongshan HospitalFudan UniversityShanghaiP.R.China Department of

The 2023 update of the chinese Society of Clinical Oncology(CSCO)Clini-cal Guidelines for Gastric cancer focuses on standardizing cancer diagnosis and treatment in china,reflecting the latest advancements in evidence-based medicine,healthcare resource availability,and precision *** updates address the differences in epidemiological characteristics,clinicopatho-logical features,tumor biology,treatment patterns,and drug selections between Eastern and Western gastric cancer *** revisions include a structured template for imaging diagnosis reports,updated standards for molecular marker testing in pathological diagnosis,and an elevated recommendation for neoadju-vant chemotherapy in stage III gastric *** advanced metastatic gastric cancer,the guidelines introduce new recommendations for immunotherapy,anti-angiogenic therapy and targeted drugs,along with updated management strategies for human epidermal growth factor receptor 2(HER2)-positive and deficient DNA mismatch repair(dMMR)/microsatellite instability-high(MSI-H)***,the guidelines offer detailed screening recommendations for hereditary gastric cancer and an appendix listing drug treatment regimens for various stages of gastric *** 2023 CSCO Clinical Guidelines for Gastric cancer updates are based on both chinese and international clinical research and expert consensus to enhance their applicability and relevance in clinical practice,particularly in the heterogeneous healthcare landscape of china,while maintaining a commitment to scientific rigor,impartiality,and timely revisions.

关键词： chinese Society of Clinical Oncology(CSCO) gastric cancer diagnosis surgery neoadjuvant adjuvant radiotherapy chemotherapy targeted therapy immunotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The chinese Society of Clinical Oncology(CSCO):Clinical guidelines for the diagnosis and treatment of gastric cancer,2021

引用

cancer Communications 2021年第8期41卷 747-795页

作者： Feng-Hua wang xiao-Tian Zhang Yuan-Fang Li Lei tang xiu-Juan Qu Jie-Er Ying Jun Zhang Ling-Yu Sun Rong-Bo Lin Hong Qiu Chang wang Miao-Zhen Qiu Mu-yan Cai QiWu Hao Liu Wen-Long Guan Ai-Ping Zhou Yu-Jing Zhang Tian-Shu Liu Feng Bi xiang-Lin Yuan Sheng-xiang Rao yan xin Wei-Qi Sheng Hui-Mian Xu Guo-xin Li Jia-Fu Ji Zhi-Wei Zhou Han Liang yan-Qiao Zhang Jing Jin Lin Shen Jin Li rui-Hua Xu Department of medical Oncology State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142P.R.China Department of Gastric Surgery State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Radiology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142P.R.China Department of medical Oncology The First Hospital of China Medical UniversityShenyangLiaoning 110001P.R.China Department of medical Oncology Zhejiang Cancer HospitalHangzhouZhejiang 310006P.R.China Department of medical Oncology Ruijin HospitalShanghai Jiaotong University School of MedicineShanghai 200025P.R.China Department of Surgical Oncology The Fourth Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiang 150001P.R.China Department of medical Oncology Fujian Cancer HospitalFuzhouFujian 350000P.R.China Department of medical Oncology Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhanHubei 430030P.R.China cancer Center of The First Hospital of Jilin University ChangchunJilin 130021P.R.China Department of Pathology State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center of Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Endoscopy Center Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142P.R.China Department of General Surgery Nanfang HospitalSouthern Medical UniversityGuangzhouGuan

There exist differences in the epidemiological characteristics,clinicopathological features,tumor biological characteristics,treatment patterns,and drug selections between gastric cancer patients from the Eastern and Western *** chinese Society of Clinical Oncology(CSCO)has organized a panel of senior experts specializing in all sub-specialties of gastric cancer to compile a clinical guideline for the diagnosis and treatment of gastric cancer since 2016 and renews it *** into account regional differences,giving full consideration to the accessibility of diagnosis and treatment resources,these experts have conducted expert consensus judgment on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes in *** 2021 CSCO Clinical Practice Guidelines for Gastric cancer covers the diagnosis,treatment,follow-up,and screening of gastric *** on the 2020 version of the CSCO chinese Gastric cancer guidelines,this updated guideline integrates the results ofmajor clinical studies from china and overseas for the past year,focused on the inclusion of research data from the chinese population for more personalized and clinically relevant *** the comprehensive treatment of non-metastatic gastric cancer,attentions were paid to neoadjuvant *** value of perioperative chemotherapy is gradually becoming clearer and its recommendation level has been *** the comprehensive treatment of metastatic gastric cancer,recommendations for immunotherapy were included,and immune checkpoint inhibitors fromthird-line to the first-line of treatment for different patient groups with detailed notes are provided.

关键词： adjuvant chemotherapy chinese Society of Clinical Oncology(CSCO) diagnosis gastric cancer immunotherapy neoadjuvant radiotherapy surgery targeted therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The chinese Society of Clinical Oncology(CSCO):clinical guidelines for the diagnosis and treatment of gastric cancer

引用

cancer Communications 2019年第1期39卷 75-105页

作者： Feng-Hua wang Lin Shen Jin Li Zhi-Wei Zhou Han Liang xiao-Tian Zhang Lei tang yan xin Jing Jin Yu-Jing Zhang xiang-Lin Yuan Tian-Shu Liu Guo-xin Li Qi Wu Hui-Mian Xu Jia-Fu Ji Yuan-Fang Li xin wang Shan Yu Hao Liu Wen-Long Guan rui-Hua Xu Department of medical Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhou 510060GuangdongP.R.China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Department of Gastrointestinal OncologyPeking University Cancer Hospital and InstituteBeijing 100142P.R.China Department of Oncology Shanghai East HospitalTongji University School of MedicineShanghai 200120P.R.China Department of Gastric Surgery Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhou 510060GuangdongP.R.China Department of Gastric cancer Tianjin Medical University Cancer Institute&HospitalNational Clinical Research Center of CancerTianjin’s Clinical Research Cancer for CancerKey Laboratory of Cancer Prevention and TherapyTianjin 300060P.R.China medical Imaging Department Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Department of Gastrointestinal OncologyPeking University Cancer Hospital and InstituteBeijing 100142P.R.China Pathology Laboratory of Gastrointestinal Tumor The First Hospital of China Medical UniversityShenyang 110001LiaoningP.R.China Department of Radiation Oncology National Cancer CenterChina and Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021P.R.China Department of Radiotherapy Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhou 510060GuangdongP.R.China Department of medical Oncology Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhan 430030HubeiP.R.China Department of medical Oncology Zhongshan Hospital Affiliated to Fudan UniversityShanghai 200032P.R.China Department of General Surgery Nanfang Hospital Affi

china is one of the countries with the highest incidence of gastric *** are differences in epidemiological characteristics,clinicopathological features,tumor biological characteristics,treatment patterns,and drug selection between gastric cancer patients from the Eastern and Western ***-chinese guidelines cannot specifically reflect the diagnosis and treatment characteristics for the chinese gastric cancer *** chinese Society of Clinical Oncology(CSCO)arranged for a panel of senior experts specializing in all sub-specialties of gastric cancer to compile,discuss,and revise the guidelines on the diagnosis and treatment of gastric cancer based on the findings of evidence-based medicine in china and *** referring to the opinions of industry experts,taking into account of regional differences,giving full consideration to the accessibility of diagnosis and treatment resources,these experts have conducted experts’consensus judgement on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic *** guideline uses tables and is complemented by explanatory and descriptive notes covering the diagnosis,comprehensive treatment,and follow-up visits for gastric cancer.

关键词： chinese Society of Clinical Oncology(CSCO) Gastric cancer Diagnosis Surgery Neoadjuvant Adjuvant Radiotherapy Chemotherapy Targeted therapy Immunotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：